Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma

Table 5 Select studies on neoadjuvant hepatic artery infusion for intrahepatic cholangiocarcinoma

Ref.	Study type	Intervention	Sample size	Conversion to resection	Tumor response
Jarnagin et al[77], 2009	Phase II trial	HAI	26	1 (4%)	14 PR, 11 SD, 1PD
Kemeny et al[78], 2011	Phase II trail	HAI + bevacizumab	18	3 (17%)	7 PR, 11 SD
Konstantinidis et al[79], 2015	Retrospective	HAI + chemotherapy	93	8 (4%)	NR
Massani et al[80], 2015	Retrospective	HAI	11	3 (27%)	5 PR, 2 SD,
Tanaka et al[113], 2002	Retrospective	HAI	11	1 (9%)	7 PR, 2 SD, 2 PD
Shitara et al[114], 2008	Retrospective	HAI	20	NR	1CR, 9PR, 8 SD, 2PD
Ghiringhelli et al[115], 2013	Retrospective	HAI	12	2 (17%)	8 PR, 3 SD, 1 PD

NR: Not reported; PR: Partial response; SD: Stable disease; PD: Disease progression; ICC: Intrahepatic cholangiocarcinoma; TACE: Transarterial chemoembolization.